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The ability of dendritic cells (DCs) to trigger tolerance or immunity is dictated by the 
context in which an antigen is encountered. A large body of evidence indicates that anti-
gen presentation by steady-state DCs induces peripheral tolerance through mechanisms 
such as the secretion of soluble factors, the clonal deletion of autoreactive T cells, and 
feedback control of regulatory T cells. Moreover, recent understandings on the function of 
DC lineages and the advent of murine models of DC depletion have highlighted the contri-
bution of DCs to lymphocyte tolerance. Importantly, these findings are now being applied 
to human research in the contexts of autoimmune diseases, allergies, and transplant 
rejection. Indeed, DC-based immunotherapy research has made important progress in 
the area of human health, particularly in regards to cancer. A better understanding of sev-
eral DC-related aspects including the features of DC lineages, milieu composition, specific 
expression of surface molecules, the control of signaling responses, and the identification 
of competent stimuli able to trigger and sustain a tolerogenic outcome will contribute to 
the success of DC-based immunotherapy in the area of lymphocyte tolerance. This review 
will discuss the latest advances in the biology of DC subtypes related to the induction of 
regulatory T cells, in addition to presenting current ex vivo protocols for tolerogenic DC 
production. Particular attention will be given to the molecules and signals relevant for 
achieving an adequate tolerogenic response for the treatment of human pathologies.
Keywords: dendritic cells, DC-based immunotherapy, tolerance, Foxp3, regulatory T cells
iNTRODUCTiON
Dendritic cells (DCs) are key controllers of innate and adaptive immunity and central regulators 
of immune tolerance (1). These functions are mainly due to the capacities of DCs to capture and 
process antigens and respond to pathogen- and self-derived danger signals in peripheral tissues. 
Additionally, migratory abilities allow competent DCs to mobilize into draining secondary lymphoid 
Abbreviations: APCs, antigen-presenting cells; cDCs, conventional dendritic cells; DCs, dendritic cells; GILZ, glucocorticoid-
induced leucine zipper; iDCs, inflammatory dendritic cells; IL, interleukin; iTregs, inducible regulatory T cells; MHC, major 
histocompatibility complex; pDCs, plasmacytoid dendritic cells; PD-L1, programed cell death ligand-1; PRRs, pattern recogni-
tion receptors; RA, retinoic acid; TGF-β, transforming growth factor beta; TLR, toll-like receptor; TolDCs, tolerogenic dendritic 
cells; Tregs, regulatory T cells.
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organs where they engage, in the presence of specific cytokines, 
antigen-specific naïve CD4+ and CD8+ T cells, thus triggering the 
activation, proliferation, and migration of these cells to peripheral 
tissues (2, 3).
It has become increasingly clear in recent years that DCs 
are a heterogeneous population of leukocytes. Various distinct 
DC subtypes have been identified, including plasmacytoid DCs 
(pDCs), conventional DCs (cDCs), and inflammatory DCs 
(iDCs), the last of which display most of the archetypical features 
of DCs and originate from circulating monocytes during inflam-
mation (4–7). The cDC subtype can be divided further, with 
mice presenting the CD8α+/CD103+ and CD11b+ subsets (8), 
and the human counterparts that express the markers BDCA-3 
and BDCA-1, respectively (5). Even though DC subtypes share 
common features, such as activation in response to pathogen 
recognition, each DC population has specialized functions (4). 
For example, pDCs produce type I interferon for viral immunity 
(9, 10), and iDCs display antimicrobial functions by producing 
the tumor necrosis factor (TNF) and the inducible nitric oxide 
synthase during infections (5, 11). In the case of cDCs, these cells 
are highly efficient at coupling innate and adaptive immunity (8). 
Moreover, the CD8α+/CD103+ cDC subset excels in the cross-
presentation of antigens to cytotoxic CD8+ T cells, while CD11b+ 
cDCs efficiently prime naïve CD4+ T cells (12).
Despite the identification of the DC lineages, it is currently 
unclear if there is a DC subtype with dedicated tolerogenic func-
tions. Indeed, rather than a specialized population, evidence indi-
cates that most DC subtypes can promote lymphocyte tolerance 
through T cell deletion, T cell anergy induction, and regulatory T 
cells (Tregs) induction (13). Furthermore, the tolerogenic features 
of DCs can be influenced by the microenvironment, expression 
of specific receptors that favor antigen presentation in subimmu-
nogenic conditions, activation of specific intracellular signaling 
responses, and by pharmacological modulation, among other 
factors. A better understanding of these mechanisms will sup-
port the development of DC-based therapies that induce specific 
Tregs, which can be applied in the treatment of immune system 
pathologies that display over-activation against self-antigens as 
well as for the treatment of transplant rejection.
For the purpose of this review, we will provide an overview of 
the function of DCs in the establishment of lymphocyte tolerance, 
with focus on Tregs induction. We will also provide perspectives 
on the mechanisms that could be exploited to induce tolerogenic 
DCs (TolDCs) in the context of human immune diseases.
CONTRiBUTiON OF DCs TO THe 
iNDUCTiON OF NATURAL AND 
PeRiPHeRAL Tregs
Dendritic cells have long been candidates for immunotherapy 
(14). In mice, these cells can be used to efficiently expand 
antigen-specific or polyclonal Tregs in autoimmune, transplant, 
and graft-versus-host diseases, among other immunological 
disorders (15–18). With the advent of intravital microscopy, the 
in vivo interactions between DCs and Tregs in lymphoid organs 
have been visualized (19). Related to this, some studies have 
found that endogenous Treg-DC interactions in the lymph node 
last longer than those established between DCs and conventional 
T cells in steady-state or during inflammation (20), thus high-
lighting the relevance of Treg and DC contacts in physiological 
conditions.
The establishment of central tolerance in the thymus 
predominantly depends on medullary thymic epithelial cells, 
which express the autoimmune regulator AIRE, a transcription 
factor required for the presentation of tissue-specific antigens to 
thymocytes (21, 22). In this context, the role of DCs in central 
tolerance appears limited, as demonstrated by studies showing 
that the thymic T cell compartment is unimpaired in mice 
displaying constitutive ablation of DCs (23, 24). However and 
despite these findings, it has been suggested that DCs could 
play a non-redundant role in the induction of natural Tregs 
(nTregs) (23, 25, 26). An advanced study of the T cell receptor 
repertoire in thymocytes showed that bone marrow-derived 
antigen-presenting cells (APCs), which include DCs, substan-
tially contribute to the composition of the nTreg T cell receptor 
repertoire (26). Interestingly, CD8α+ cDCs can acquire and 
present autoimmune regulator-dependent antigens derived from 
medullary thymic epithelial cells to nTregs (26).
In addition to sustain nTreg selection, DCs can promote nTreg 
development in the thymus via the CD27–CD70 costimulation 
axis (27). Expression of CD70 on epithelial cells and DCs, par-
ticularly those of the CD8α+ subset, contributes to nTreg survival 
(27). Thus, there is growing evidence indicating that DCs could 
be actively involved in promoting thymic Treg development. 
Nevertheless, it remains to be discovered if the repertoire, fre-
quency, and function of nTregs are dependent on a specialized 
DC subset.
In secondary lymphoid organs and in non-lymphoid tissues, 
the dynamics of DC and Treg populations are closely intertwined 
(28). This notion is derived from observations in Foxp3DTR mice, 
in which the depletion of Tregs leads to a notable increase in DCs 
frequency (29). The mechanism by which Tregs exert control 
over DC expansion is not fully understood, but it does depend 
on the cytokine Flt3L, a crucial regulator of DC commitment (8, 
30). In fact, in vivo Flt3L treatment results in more DCs and a 
concomitant increase in the number of inducible Tregs (iTregs) 
(31). In contrast, Flt3l−/− mice show a 10-fold reduction in cDCs 
together with lower Treg cell counts (28). Even though evidence 
suggests that Flt3L leads to Treg expansion via a DC-dependent 
mechanism, this cytokine may also influence additional myeloid 
cell types, which in turn could impact Treg homeostasis inde-
pendently of DCs. Nevertheless, data acquired from models of 
acute DC depletion, as triggered by administering a diphtheria 
toxin to CD11c-DTR mice, also demonstrated a two- or threefold 
reduction of iTregs (28, 32). These findings indicate that DCs are 
active regulators of Treg numbers in vivo.
Also in peripheral tissues, the maintenance of Tregs is depend-
ent on costimulation by DCs. Despite some reports indicating that 
the absence of CD80/86 molecules on DCs leads to higher expres-
sion of Foxp3 (33), additional work has revealed that interactions 
mediated by CD80 and CD86 on APCs with the CD28 receptor 
on T cells are key for maintaining iTregs (34–37). These studies 
have been recently revisited in experiments using CD11c DTA 
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mice (38), which constitutively lack DCs (32). Findings demon-
strate that the absence of CD80/86 in the CD11c+ compartment 
results in a reduction of peripheral Tregs (32). Thus, in addition 
to major histocompatibility complex (MHC)-II molecules (28), 
iTreg maintenance critically relies on the expression of costimula-
tory molecules by DCs (32).
Another mechanism through which DCs can maintain Treg 
functions is via expression of the programed cell death ligand-1 
(PD-L1) molecule. Interaction between PD-L1 on DCs and PD-1 
receptor on T cells promotes the expression of Foxp3+ Tregs, 
whereas blocking PD-L1 in vivo curtails Treg conversion during 
tumor challenge (39). Furthermore, the PDL1/2-PD1 interaction 
between DCs and Treg cells prevents autoimmunity of the central 
nervous system (40). In addition to the activation molecules, the 
migratory abilities of DCs may be relevant in promoting T cell 
tolerance. Indeed, migratory DCs have superior abilities than 
resident DCs to induce Treg development for the same antigen 
(41), which may be important to consider in the design of 
DC-based therapies.
Altogether, these findings indicate that DCs promote the 
induction of natural and iTregs via a variety of mechanisms that 
include the expression of multiple costimulatory and coinhibitory 
signaling pathways, the secretion of regulatory factors, migration, 
and the ability to present antigens. The advent of innovative 
models for selective ablation of cDCs using discriminating mark-
ers, such as the zinc finger transcription factor, zDC or the DC 
receptor, DNGR-1 (42, 43), will provide invaluable information 
toward addressing the role of DC lineages in the establishment of 
lymphocyte tolerance.
CONTRiBUTiON OF DC SUBTYPeS TO  
T CeLL TOLeRANCe
Current understanding dictates that antigen presentation in the 
absence of pathogen/danger detection leads to T cell tolerance of 
self or non-self antigens (4, 13). Nevertheless, continuing discov-
eries on the complexity and diversity of the DC network make 
it necessary to reassess current knowledge of DC subsets in the 
establishment of T cell tolerance. In particular, markers histori-
cally attributed to DCs, such as MHC-II and the integrin CD11c, 
do not actually discriminate among DC subpopulations and often 
overlap with additional members of the mononuclear phagocyte 
system, including monocytes and macrophages, especially under 
inflammatory conditions (44). Through the discovery of specific 
DC markers and a review of DC lineages based on ontogeny, 
researchers will be able to better understand the contribution of 
DC subtypes to Treg development in a variety of scenarios.
CD8α+/CD103+ cDCs
Conventional DCs expressing the CD8α+ marker can be found 
in lymphoid organs while cDCs located in non-lymphoid tissues 
express the marker CD103+, with the exception of a subpopula-
tion of DCs in the intestine (5, 7, 45, 46). The CD8α+/CD103+ 
subsets share a common origin and function and depend on the 
transcription factors Batf3, IRF8, and Id2 for development (6, 
8, 44, 46–48). Given the ability of these subsets to cross-present 
antigens, CD8α+ and CD103+ DCs are traditionally associated 
with the cross-priming of pathogens- and tumor-derived antigens 
to CD8+ T cells (5). Moreover, in the absence of inflammation, 
CD8α+/CD103+ DCs can also regulate the induction of Tregs and 
mediate T cell tolerance (8, 21). Functionally, splenic CD8α+ DCs 
are superior at inducing Foxp3+ T cell differentiation than CD8α− 
DC counterparts due to their ability to produce transforming 
growth factor beta (TGF-β) (39, 49). Furthermore, CD8α+ cells 
have demonstrated proficient abilities to induce iTregs in in vivo 
studies of antigen targeting via the expression of antibodies spe-
cific to endocytic receptors, such as the C-type lectins DEC205 
and DNGR-1 (50, 51). These results indicate that CD8α+ DCs can 
be manipulated to induce iTreg differentiation in vivo by means 
of antigen delivery.
In tissues, CD8α+/CD103+ DCs related to the gut-associated 
lymphoid tissue (GALT) are critically involved in oral tolerance 
and in inducing the de novo differentiation of Foxp3+ T cells (52). 
However, the ability of CD8α+/CD103+ DCs to induce iTregs in vivo 
is not exclusive, as indicated by studies in batf3−/− mice, which lack 
the CD8α+/CD103+ DC subsets but display normal frequencies of 
intestinal Tregs, indicating that additional APCs can compensate to 
safeguard Treg homeostasis in the intestine (45).
CD11b+ cDC
Conventional DCs expressing CD11b+ are found across lymphoid 
organs and non-lymphoid tissues, but their function in tolerance 
has been challenging to address, partially since these cells express 
markers that are shared with macrophages and monocytes, such 
as CD11c, MHC-II, and CD11b (7). Nevertheless, in inflamed 
skin, dermal CD11b+ DCs display a marked ability to induce 
Foxp3+ T cells (53). Furthermore, the capacity of DCs to mediate 
Treg induction in the dermis is attributable to the CD11b+CD103− 
subtype (54). These findings indicate that CD11b+ DCs can 
regulate the homeostasis of Tregs in the skin.
Nevertheless, and as noted for CD103+ DCs, the selective abla-
tion of CD11b+ DCs does not alter Treg frequencies, indicating 
that these cells may be sufficient but not necessary for Treg cell 
homeostasis (55). The discovery of new surface molecules allow-
ing for the distinction of bona fide CD11b+ DCs such as CD24, 
CD64, and MerTK will provide relevant information on this cell 
type in Treg induction.
Plasmacytoid DCs
Plasmacytoid dendritic cells found in the bone marrow and 
lymphoid organs, which express the markers CD11c, B220, 
Siglec-H, and BST2, depend on the E2-2 transcription factor for 
development (7) and produce large amounts of type I interferon 
in response to viral recognition (7). Although the involvement 
of pDCs in antigen presentation to T cells is a matter of debate 
(56), MHC-II-restricted antigen presentation by pDCs promotes 
Foxp3+ T cell expansion that results in protection against experi-
mental autoimmune encephalomyelitis (57). Furthermore, pDCs 
with dietary antigens can mediate oral tolerance via CD4+ and 
CD8+ T cells (58) and induce tolerance to vascularized cardiac 
allografts via the generation of Foxp3+ T cells (59). In humans, 
pDCs isolated from blood induce Foxp3+ T cells (60), which is 
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attributed to the expression of the enzyme indoleamine 2,3-diox-
ygenase, PD-L1, and the inducible costimulator-ligand (10, 61, 
62). In addition, pDCs residing in the human thymus drive 
nTreg development ex vivo (63), and stimuli such as cytosine-
phosphate-guanine and the thymic stromal lymphopoietin have 
shown to promote this function (64). These findings indicate 
that human pDCs have the potential to be used as tools for Treg 
induction. In contrast to human counterparts, murine pDCs 
display limited abilities to induce Tregs (10). On the other hand, 
antigen targeting to the human BDCA-2 molecule in B6.BDCA2 
transgenic mice results in antigen-specific tolerance and an 
increased Tregs/T effector ratio (65).
Altogether, current evidence indicates that pDCs strongly 
contribute to Treg homeostasis and could be attractive candidates 
for immunotherapy treatments against several conditions, such 
as transplant rejection, autoimmune diseases, and cancer (66).
inflammatory DCs
Inflammatory dendritic cells present during infection/inflam-
mation, are derived from monocytes, and express the markers 
CD11c, MHC-II, CD11b, and CD64. iDCs release large amounts 
of inflammatory cytokines upon pathogen recognition, including 
TNF and the inducible nitric oxide synthase (7). Moreover, iDCs 
drive Th1- and Th17-mediated immunity, a feature also recorded 
in humans (67). Given that these cells are not present in steady-
state conditions, their role in maintaining Treg homeostasis 
in vivo is not fully understood. Nevertheless, in vitro models of 
DC generation have been widely used. DCs stimulated by the 
granulocyte macrophage colony-stimulating factor (GM-CSF), 
plus or minus interleukin (IL)-4, induce large numbers of cells 
that resemble those originated under inflammatory contexts (8, 
68), and these cells have been broadly used as tools to differenti-
ate Tregs ex vivo (15, 69). However, recent findings indicate that 
GM-CSF-derived DCs are composed by a heterogeneous mixture 
of macrophages and DCs, which are indistinguishable through 
quantification of CD11c and MHC-II expression (70). It is also 
currently unclear which population is mediating Treg induction.
Thus, current data indicate that while DCs facilitate the induc-
tion of Tregs, there is no strict dependency on any DC lineage to 
sustain this function. Rather, it seems that several immune cell 
types, depending on the scenario, can contribute to the regulation 
of Treg cell homeostasis.
ROLe OF eXOGeNOUS AND 
eNDOGeNOUS TRiGGeRS OF 
TOLeROGeNiC DCs
The ability of DCs to favor Treg homeostasis and restrict T cell 
immunity can be fine-tuned by several extracellular and intracel-
lular factors. These factors include microenvironmental features, 
the expression of surface molecules, and the selective activation of 
specific signaling pathways that promote Treg induction. In addition, 
TolDCs have been generated and studied in contexts of pharmaco-
logical modulation. The aspects that contribute to the programing 
of DCs in regards to triggering T cell tolerance are described below.
Microenvironment
The homeostasis of Tregs can be specifically regulated depend-
ing on location, metabolism of dietary products, or exposure 
to microbes or tumors (71, 72). In the microenvironment of 
a tumor, cancer cells can produce suppressive factors that 
promote DCs to induce Tregs that can, in turn, contribute 
to tumor progression (71). For example, DCs isolated from 
tumor-bearing animals are programed by cancer cells to pro-
mote Treg proliferation via TGF-β production (73). Moreover, 
apoptotic cells resulting from physiological processes are 
potent inducers of tolerance via DCs (74). Interestingly, early 
traslocation of annexin A1 contributes an essential tolerogenic 
property to apoptotic cells, conferring their ability to suppress 
DC activation and cellular immunity (75). Annexin A1 on 
apoptotic cells critically interferes with TLR signaling path-
ways upstream of NFκB activation and, in turn, preventing 
antigen-specific T cell responses (75). In addition, clearance of 
dead cells by DCs, which requires dedicated receptors such as 
DEC205 (76), results in the induction of Tregs (77). In in vivo 
models, the apoptotic cargo is preferentially captured by the 
CD8α+ lineage of DCs, which are able to mediate tolerance to 
cell-associated antigens (78).
Another characteristic site for Treg presence is the gut (52, 
71, 72, 79, 80). Here, GALT–CD103+ DCs specialize in the syn-
thesis of retinoic acid (RA) and are the cell type predominantly 
responsible for Treg generation (52, 79). RA is a metabolite of 
vitamin A that regulates Treg induction by enhancing TGF-β-
induced conversion of CD4+ T cells to Foxp3+ T cells (33, 81, 82). 
Specifically, RA sustains the differentiation of Foxp3+ T cells by 
acting in cis on naïve T cells or in trans by relieving the inhibition 
exerted by CD4+ memory T cells on iTreg development (33, 81, 
82). CD103+ DCs isolated from the small intestine lamina propria 
can synthesize RA and secrete bioactive TGF-β at levels sufficient 
to trigger Treg differentiation (52, 71). Notably, the effect of RA in 
promoting Tregs is not restricted to the intestine. In the skin, RA 
production is attributed to dermal CD11b+ DCs, which trigger 
de novo iTreg differentiation with higher efficiency than CD103+ 
counterparts (54). Even though the tissue-associated signals that 
lead to RA production by distinct DC subsets in the gut and 
skin are unclear, these findings indicate that the ability to induce 
iTregs is not an attribute of a dedicated DC subtype and that the 
outcome of the immune response is dictated by the integration of 
multiple environmental cues.
In a physiological context, DCs may also contribute to the 
maintenance of Treg homeostasis through the induction of 
tolerance to commensal microbiota (83, 84). Although the 
predominating standpoint is that DCs activated with microbes 
via pattern recognition receptors (PRRs) provide the signals 
necessary to elicit T cell immunity, it has been also reported 
that Tregs can arise in non-sterile conditions. This notion is 
supported by studies in germ-free mice, which display reduced 
Tregs frequency (85, 86). In fact, certain intestinal bacteria, 
including Clostridium strains and the human commensal bacte-
ria Bacteroides fragilis, have been found to promote Treg devel-
opment (85, 87). These findings open new avenues for studying 
the role of DCs in Treg homeostasis in the context of microbe 
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recognition, particularly against commensal and/or symbiotic 
microbiota. However, extensive studies must be carried out to 
reveal the mechanisms by which these particular microbes are 
able to induce Tregs and prevent T cell immunity or even Treg 
plasticity. Identification of these particular signatures would be 
greatly relevant to the advancement of DCs use in the treatment 
of diseases as there are additional microbial compounds, such as 
the fungal β-glucan curdlan, that trigger reprograming of Tregs 
into Th17 cells, which may result in immunity rather than toler-
ance depending on the conditions (88).
The in  vivo identification of microbial-derived components 
that can trigger Tregs is an emerging field with many prospects 
related to clinical immunology. Along these lines, it remains to 
be determined whether the effects of commensal microbiota are 
indeed mediated by DC subtypes.
SURFACe MOLeCULeS AND ACTivATiON 
OF SiGNALiNG ReSPONSeS
Dendritic cell function can be modulated by the expression 
of surface molecules and activation of signaling cascades 
responsible for promoting Treg cells. In addition to the endo-
cytic receptors such as DEC205 that can be exploited for Treg 
induction, certain surface molecules can confer tolerogenic 
properties to DCs. On one hand, expression of the TGF-β 
activating integrin αvβ8 by DCs is required for efficient Treg 
induction (89, 90). In fact, mice deficient in αvβ8 in DCs have 
decreased abilities to generate iTregs. This limitation causes 
autoimmunity and colitis in mice (89, 90), indicating that 
TGF-β processing by DCs is a key feature for maintaining Treg 
homeostasis.
Tolerogenic cell death
Necrotic/apoptotic cells
Self Ags
Disease-related Ags
receptors
IL-10
receptor
CCR7
αv integrin
Latent TGF-β
Active TGF-β
TLRs
Commensal PAMPs
Cancer cell-
produced IL-10
Pharmacological Stimuli
Dexamethasone
VitD3
Rapamycin
NF-kB
Antigen-
processing 
machinery
A20
STAT3
GILZ
mTOR
β-catenin
E-cadherin
Wnt
Glycolysis
inhibition
RALDH
Vitamin A
Retinoic 
Acid
2-deoxyglucose 
(2-DG)
CD86
CD80
MHC-II
Treg
FiGURe 1 | Stimuli and mechanisms that induce the generation of TolDCs. Several stimuli can trigger different intracellular mechanisms that reprogram 
TolDCs to induce Tregs. TLR2 triggering results in Treg induction (91). These include activation via TLR2, expression of αv integrin for activation of TGF-β, and 
expression of endocytic receptors responsible to divert the antigenic cargo for presentation in tolerogenic contexts. Furthermore, the inhibition of glycolysis upon 
TLR stimulation by 2-deoxyglucose, promotes Treg induction (93). Moreover, the ubiquitin-editing protein A20 is a crucial regulator of TLR-driven DC activation 
responsible for preventing autoimmunity (94). PRR-independent mechanisms of DC activation, such as through E-cadherin and β-catenin, lead to the induction of 
IL-10-producing T cells with autoimmune competency (95). Likewise, expression of the retinoic-acid synthesizing enzyme 2 (RALDH2) in DCs allows the synthesis 
and secretion of RA, a crucial regulator of Treg homeostasis (80, 81). Furthermore, additional physiological stimuli associated with the induction of tolerance, such as 
apoptotic bodies, have double functions: (i) their internalization by DCs induces tolerance itself; and (ii) these are a broad source of self-antigens that can be loaded 
onto MHC-II molecules and presented to CD4+ T cells (77). Additionally, specifically selected malignant cells produce IL-10, which is considered a mechanism of 
immune evasion since this cytokine inhibits MHC-I expression on cancer cells and strongly induces a tolerogenic phenotype on DCs by inducing IL-10 expression in 
a paracrine manner (96). Finally, pharmacological stimuli are able to trigger different transcription factors (e.g., GILZ, mTOR) that activate tolerogenic-associated 
protein expression on DCs (97, 98).
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On the other hand, evidence indicates that signaling via PRRs 
in DCs also contributes to the establishment of lymphocyte toler-
ance via Tregs (Figure 1). Toll-like receptor 2 (TLR2) expression 
in DCs couples innate immunity to the induction of Foxp3+ 
T cells through activation of IL-10 and the RA-metabolizing 
enzyme retinaldehyde dehydrogenase 2 (91). Importantly, TLR2 
signaling in DCs mediates suppression against autoimmunity 
via the induction of Tregs (91). In addition to TLR2, additional 
PRRs can induce IL-10 in DCs, also leading to the induction 
of Treg responses. The modulation of IL-10 secretion by DCs 
via the DC-SIGN receptor has been associated with Foxp3+  
expression in naïve T cells in a murine model of nephrotoxic 
nephritis (92). Moreover, a monoclonal antibody to P-selectin, 
which also interacts with DC-SIGN, induces IL-10 secretion 
in human DCs that, in turn, contribute to the induction of 
CD4+CD25+Foxp3+ T cells (92).
Regulators of PRR signaling in DCs can also dictate the 
balance between T cell tolerance and immunity. The ubiquitin-
editing enzyme A20, an anti-inflammatory protein involved in the 
attenuation of NF-κB signaling downstream of TLRs, is a crucial 
regulator of immune tolerance (Figure 1) (94). DC-specific dele-
tion of A20 results in autoimmunity and systemic inflammation 
in mice, demonstrating the role of this protein as a key regulator 
in DC tolerance, which may be important to consider for clinical 
applications.
On the other hand, DCs able to induce Tregs can also be 
generated in the absence of PRR engagement. For instance, the 
maturation of DCs in response to the disruption of cell-to-cell 
interactions through the blockade of E-cadherin results in 
the induction of Tregs (95). This form of DC activation seems 
partially dependent on β-catenin (99). Interestingly, β-catenin 
signaling in DCs may also be a key controller of tolerance (83). 
The expression of β-catenin in DCs regulates the expression of 
RA, TGF-β, and IL-10 (Figure  1) (83). Importantly, selective 
ablation of β-catenin in CD11c-expressing cells leads to reduced 
Foxp3+ Tregs in the intestine (83), highlighting the contribution 
of specific signaling pathways in programing TolDCs. In this 
context, there are ongoing efforts aiming to identify gene expres-
sion signatures that distinguish between PRR-activated DCs and 
mature homeostatic DCs. These studies may shed light on the 
regulatory gene networks relevant to TolDC programing (5).
Besides changes in gene expression, the process of DC activa-
tion also involves a metabolic reprograming required to elicit T 
cell immunity. This process includes a rapid increase in glycolysis, 
which is essential to fulfill the biosynthetic and bioenergetic 
demands of activated DCs (93, 100). Inhibition of glycolysis in 
activated DCs through 2-deoxyglucose, an inhibitor of hexoki-
nase, biases DCs to induce Foxp3+ T cells (93). This observation 
suggests that gaining better insights into the metabolic programs 
of steady-state versus activated DCs may be useful toward 
ultimately programing TolDCs for therapeutic use. In humans, 
TolDCs are characterized by increased catabolic pathway signal-
ing, oxidative phosphorylation, mitochondrial oxidative activity, 
and fatty acid oxidation, as compared to activated DCs. In fact, 
the inhibition of fatty acid oxidation prevents the functioning of 
TolDCs and partially restores T cell stimulatory capacity (101). 
These data suggest that interfering with metabolic checkpoints 
in DC maturation may be an interesting strategy for programing 
TolDCs for therapeutic purposes.
PHARMACOLOGiCAL MODULATiON OF 
TolDCs
The phenotypic plasticity of DCs can be modulated by a variety 
of stimuli with different nature and origin (Figure 1). Although 
there is currently no absolute consensus about the phenotype 
and characteristics of TolDCs, several studies support the notion 
that these cells must be able to induce a Foxp3+ Treg phenotype 
from naïve T cells (83, 84, 102, 103). From a clinical perspec-
tive, DC activation can be pharmacologically altered to obtain 
DCs capable of mediating T cell tolerance. Several cytokines, 
anti-inflammatory, and immunosuppressive drugs trigger a 
tolerogenic phenotype by interfering with checkpoints of DC dif-
ferentiation and activation. These include glucocorticoids, vitamin 
D, aspirin, rapamycin, rosiglitazone, heme oxygenase-1 inducers, 
and andrographolide, among others (104–112). In addition, the 
ability of different cytokines to generate TolDCs has been tested, 
with IL-10 and TGF-β found as the most effective  factors. DCs 
cultured in the presence of IL-10 and or TGF-β trigger anergy 
in naïve and memory T cells and are also able to activate T cells 
with an IL-2low, IFN-γlow, and IL-10high Foxp3+ profile (10, 113). In 
fact, IL-10 is also involved in the differentiation of Foxp3+ Tregs 
in human in vitro models (11).
Regarding the pharmacological modulation of DCs in human, 
different protocols have been developed by adapting strategies 
used in mouse cells. Dexamethasone, vitamin D3, and rapa-
mycin, in conjunction with the GM-CSF and IL-4, are the most 
used reagents in the ex vivo differentiation of peripheral blood 
monocytes into TolDCs (114). Dexamethasone, a glucocorticoid 
widely used to treat autoimmune diseases and graft rejection, 
mantains an immature DC phenotype that is associated with low 
expression of human leukocyte antigen II and co-stimulatory 
molecules. In addition, dexamethasone-treated DCs maintain 
expression of the chemokine receptor CCR7, suggesting that these 
DCs may retain migratory skills, a characteristic necessary for 
use in immunotherapy (115–117). Interestingly, dexamethasone 
stimulation in DCs also upregulates the glucocorticoid-induced 
leucine zipper (GILZ) protein and promotes the differentiation 
of antigen-specific CD25(high)Foxp3+CTLA-4/CD152+ and IL-10-
producing Tregs able to inhibit CD4+ and CD8+ T cell responses 
(118). In fact, GILZ expression by DCs is an important regu-
lator of Tregs (97). CD11c-GILZhi transgenic mice, which 
overexpress GILZ in the CD11c compartment, display an 
accumulation of Foxp3+ Tregs in spleen and in central and 
peripheral lymphoid organs of aged animals (97).
For its part, vitamin D3 (1,25-dihydroxyvitamin D3) promotes 
a tolerogenic phenotype in human monocyte-derived DCs via 
the activation of glucose metabolism. This effect is mediated by 
the PI3K/Akt/mTOR pathway, which controls the induction and 
maintenance of tolerogenic functions in DCs, stimulating the 
generation of Tregs (98, 119). In turn, rapamycin, an antibiotic of 
the macrolide family that possesses immunosuppressive proper-
ties, inhibits the maturation and effector functions of DCs. Indeed, 
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murine rapamycin-treated DCs are inferior stimulators of synge-
neic T cells that do not alter antigen uptake or in vivo homing to 
lymphoid tissue (111). Additionally, rapamycin treatment inhibits 
the ability of DCs to produce IL-12 and TNFα and can induce the 
proliferation of CD4+CD25+Foxp3+ Tregs (108, 120).
Taken together, the current evidence strongly supports that 
TolDCs generated by a single or combination of drugs could be an 
effective therapeutic approach to induce antigen specific Tregs in 
a variety of scenarios. In this regard, IL-10 and rapamycin appear 
to be the most suitable agents for generating TolDCs that could 
be applied in the treatment of human diseases.
DC-BASeD iMMUNOTHeRAPY AND THe 
iNDUCTiON OF TOLeRANCe: wHeRe 
ARe we?
Over the last decade, different DC-based immunotherapies 
have been used to stimulate immune responses, and some have 
shown objective clinical benefits in patients with different types 
of cancer (121–125). Currently, several immunotherapeutic 
approaches are being studied, including for autoimmune condi-
tions, allergies, and transplant rejection. All of these pathologies 
require permanent induction of T cell tolerance, as triggered by 
TolDC and orchestrated by proficient Treg functions. Indeed, the 
main target of TolDC immunotherapy should be the induction 
of tissue/organ infiltrating Tregs. Clinical data on TolDC-based 
immunotherapies remain limited, and the majority of studies 
are in preclinical stages. These studies focus on the development 
of safe and well-tolerated TolDCs with an anti-inflammatory 
phenotype and a preferential capacity to induce Tregs (126–128).
Regarding allergy treatments, atopic diseases are largely 
dominated by T helper type 2 immune responses that lead to 
an accumulation of eosinophils, immunoglobulin E produc-
tion, and the sensitization of tissue mast cells (129). In ex vivo 
models, TolDCs… have shown to suppress the T helper type 
2 immune response by inducing/expanding IL-10-expressing 
CD25+Foxp3+LAG-3+CTLA-4+ Tregs (130). Moreover, in  vitro 
dexamethasone-induced human TolDCs are able to generate 
IL-10-expressing T cells specific for the Hev b5 antigen, a princi-
pal latex allergen (128).
On the other hand, autoimmune diseases are an issue of public 
health due to their heterogeneity and diverse clinical manifesta-
tions. Several studies in murine models of rheumatoid arthritis 
have demonstrated the efficacy of TNF-, IL-10-, and dexameth-
asone-treated TolDCs to treat collagen-induced arthritis, an 
experimental model for inflammatory joint diseases (131–133). 
In fact, the first prospective phase I clinical trial in patients with 
rheumatoid arthritis was recently concluded (134). In this trial, 
patients treated with autologous modified TolDCs and pulsed 
with citrullinated peptide antigens showed changes in the Treg/T 
effector ratio, where in 11 out of 15 treated patients, there was 
at least a 25% reduction in CD4+CD25+CD127+ T effector cells. 
However, Tregs increased by ≥25% in only 5 out of 15 treated 
patients (134). Importantly, this clinical trial has demonstrated 
the safety of this therapeutic approach as well as its effects on 
patients’ immunological parameters.
CONCLUSiON
In conclusion, and despite the substantial advances made in 
recent years regarding the development and function of TolDCs, 
it remains to be determined whether this knowledge can be 
applicable to the clinic. The ultimate success of TolDC-based 
therapies will be dictated by gaining in-depth understanding of 
the mechanisms by which TolDCs suppress autoreactive lympho-
cytes and induce Tregs; and by obtaining better insights regarding 
the mechanisms by TolDC suppress autoimmunity, allergies, and 
transplant rejection. These aspects include the stability/commit-
ment of generated TolDC, especially in an in vivo inflammatory 
milieu, among others.
In addition, as there is no current consensus about which stimuli 
would be more reliable in inducing a committed TolDC phenotype, 
it is highly plausible that specific combination of these triggers, 
or even an additional stimuli yet to be identified, are needed to 
reach this phenotype. A third aspect to be addressed is the clear 
identification of specific receptors and the downstream signaling 
pathways that can be triggered in DCs to induce Treg responses. 
In this context, studies using high-throughput approaches (e.g., 
proteomics and genomics) will be of great help to identify the 
crucial genes/proteins networks involved in programing TolDCs 
suitable for Treg induction. This knowledge will assuredly facilitate 
the near-future design of reliable and clinically effective TolDCs for 
the treatment of several human diseases and conditions.
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